Barclays lowered the firm’s price target on Pacira to $40 from $50 and keeps an Overweight rating on the shares post the Q4 results. The analyst says 2024 is turning into a transition year for the company as the new management team is aiming to solidify long-term growth. The firm believes Pacira has restructuring plans in place to support more sustainable growth over the medium term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira Pharmaceuticals CFO Transition and Financial Update
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira reports Q4 EPS 89c, consensus 88c
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy